Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Primary Aldosteronism, Statin, Mineraloc...
Phase PHASE4
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Simvastatin combined with Amlodipine besylate — 6-month treatment of Simvastatin combined with Amlodipine besylate
  • Drug: Simvastatin combined with Spironolactone and Amlodipine besylate. — 6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
  • Drug: Amlodipine besylate combined Spironolactone — 6-month treatment of Amlodipine besylate combined with Spironolactone

Primary Outcomes

  • changes in plasma aldosterone levels (6 month)
  • changes in 24-hour urinary aldosterone levels (6 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-09-10
Completion: 2026-09-30
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Third Military Medical University
Contact Information
Study Contact:
sun fang
+862368729587
sun_fang2007@163.com
Jingjing Wang
+86-02368757140
wii1017@163.com
No. 10 Changjiang River Branch, Yuzhong District,Chongqing, China
Interventions
  • Drug: Simvastatin combined with Amlodipine besylate — 6-month treatment of Simvastatin combined with Amlodipine besylate
  • Drug: Simvastatin combined with Spironolactone and Amlodipine besylate. — 6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
  • Drug: Amlodipine besylate combined Spironolactone — 6-month treatment of Amlodipine besylate combined with Spironolactone
Study Locations (1 sites)
No. 10 Changjiang River Branch, Yuzhong District,Chongqing, China, Chongqing, Chongqing Municipality 400042 China
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of primary aldosteronism Exclusion Criteria: * Allergy to drugs in this study * Pregnancy * Severe liver and kidney dysfunction * Mental illness
Conditions Endocrine Disease, Metabolic Disorders, ...
Phase Not Applicable
Enrollment 8000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The aim is to establish an effective and practical early warning model for endocrine and metabolic diseases based on an environmental-gene-protein panoramic network, to uncover new mechanisms underlying the onset and progression of these diseases, and to screen for novel therapeutic targets.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: observe — A single observational cohort of study participants undergoing baseline biochemical screening for autonomous aldosterone secretion (AAS). No experimental interventions or treatments are administered. All participants receive standard clinical care and undergo standardized baseline assessments, including measurement of plasma aldosterone concentration (PAC) and plasma renin concentration (PRC) for AAS classification, as well as collection of demographic, clinical, biochemical, anthropometric data and biospecimens for proteomic analysis.

Primary Outcomes

  • The prevalence of autonomous secretion of aldosterone (The follow-up period from baseline enrollment to the completion of follow-up examinations was approximately 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-12-25
Completion: 2026-12-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 8000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Qifu Li
Principal Investigators:
  • Qifu Li, MD, PhD, Chief Physician (PRINCIPAL_INVESTIGATOR) - First Affiliated Hospital of Chongqing Medical University
Contact Information
Study Contact:
Qifu Li, MD, PhD, Chief Physician
+8618696676815
liqifu@yeah.net
Shumin Yang, MD, PhD, Chief Physician
+8615523552235‬
443068494@qq.com
Yunyan Liao, MD
15823939745
2215133087@qq.com
The First Affiliated Hospital of Chongqing Medical University
Interventions
  • Other: observe — A single observational cohort of study participants undergoing baseline biochemical screening for autonomous aldosterone secretion (AAS). No experimental interventions or treatments are administered. All participants receive standard clinical care and undergo standardized baseline assessments, including measurement of plasma aldosterone concentration (PAC) and plasma renin concentration (PRC) for AAS classification, as well as collection of demographic, clinical, biochemical, anthropometric data and biospecimens for proteomic analysis.
Study Locations (1 sites)
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Eligibility Criteria
Inclusion Criteria: * All individuals who voluntarily participated in the physical examination Exclusion Criteria: Participants with incomplete data
Conditions Hypertension, Obesity & Overweight
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Hypertension is the leading risk factor for death globally, affecting approximately 30% of adults in the United Kingdom. Obesity is also a serious and ongoing epidemic, with global obesity rates having more than tripled in men and doubled in women, since 1975. In the United Kingdom, 64% of the adult population are overweight or obese. Hypertension and obesity share a well-established association, with obesity being responsible for the development of hypertension in 40-78% of cases. In young adults, this link between body size and blood pressure (BP) is much stronger that in older adults. Since overweight and obesity are among the most common and modifiable causes of high BP, weight loss induced by lifestyle-changes is recommended for overweight or obese patients with hypertension. However, lifestyle interventions, even when successful, result in only moderate weight loss, which is not maintained in the majority of cases. A meta-analysis of randomised controlled trials demonstrated that lifestyle-interventions lead to an average net weight reduction of 5.1 kg, accompanied by a significant, but modest, \~4 mmHg reduction in BP. Weight loss interventions could play a crucial role in the treatment of obesity-related hypertension in young adults. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, originally developed for the treatment of type 2 diabetes, are safe and clinically effective anti-obesity drugs. Recent data show a 10-20% placebo-adjusted reduction in body weight in overweight or obese adults without diabetes using the GLP-1 analogue semaglutide or the dual GLP-1/GIP receptor agonist tirzepatide, with the majority of weight loss achieved within the initial six months. The substantial weight loss induced by these drugs is accompanied by a significant reduction in BP. Two recent meta-analyses showed that semaglutide is associated with a \~5 mmHg placebo-adjusted reduction in clinic systolic BP (SBP). A sub-study of the SURMOUNT-1 trial reported a \~10 mmHg reduction in 24-h ambulatory SBP with tirzepatide. Most participants in these studies were normotensive or had well-controlled hypertension. Furthermore, antihypertensive medication use declined amongst those receiving anti-obesity drugs meaning the BP-lowering effect of weight loss, elicited by these drugs, is probably underestimated. These data suggest that the new anti-obesity drugs could be effective in managing overweight or obesity-related hypertension. Furthermore, it may be possible to cure hypertension in at least some young adults, removing the need for life-long antihypertensive treatment. However, the magnitude and time course of BP reduction elicited by these new anti-obesity drugs remain uncertain. The primary aim of this feasibility study is to assess the extent and trajectory of BP reduction achieved through intensive weight loss in overweight or obese adults with stage 1 hypertension and compare this to current…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tirzepatide — 2.5mg for 4 weeks, 5mg for 4 weeks, 7.5mg for 4 weeks, 10mg for 12 weeks
  • Drug: Anti-Hypertensive medications — Anti-hypertensive drug therapy as per local and national guidelines

Primary Outcomes

  • Ambulatory systolic blood pressure (Baseline to week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01
Completion: 2029-01
Eligibility
Age: 18 Years – 40 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust
Collaborators: National Institute for Health Research, United Kingdom
Contact Information
Study Contact:
James Goodman, MRCP PhD
+44 01223 336806
james.goodman11@nhs.net
Cambridge University Hospitals NHS Foundation Trust
Interventions
  • Drug: Tirzepatide — 2.5mg for 4 weeks, 5mg for 4 weeks, 7.5mg for 4 weeks, 10mg for 12 weeks
  • Drug: Anti-Hypertensive medications — Anti-hypertensive drug therapy as per local and national guidelines
Study Locations (1 sites)
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire CB2 0QQ United Kingdom
Eligibility Criteria
Eligibility criteria for randomisation Inclusion Criteria: * Aged 18 to 40 years (inclusive) * Body mass index (BMI) ≥27 kg/m2 * Clinical diagnosis of primary (essential) hypertension as per NICE guidance * Unattended brachial SBP ≥135 and/or DBP ≥85 mmHg and \<160/100 mmHg * Maximum of one antihypertensive medication Exclusion Criteria: • Anything in medical notes suggesting unsuitable in the opinion of the investigator Eligibility criteria for participation in weight loss arm Inclusion criteria: * Written informed consent * Aged 18 to 40 years (inclusive) * Body mass index ≥27 kg/m2 * Clinical diagnosis of primary (essential) hypertension as per NICE guidance * Unattended brachial SBP ≥135 and/or DBP ≥85 mmHg and \<160/100 mmHg * Maximum of one antihypertensive medication Exclusion criteria: The presence of any of the following will preclude participant inclusion: * Known or suspected secondary hypertension * Hypersensitivity to any of the study drugs or excipients * Currently taking drugs likely to have interactions with tirzepatide * Diagnosis of type 1 or type 2 diabetes mellitus or current usage of insulin or other injectable drugs for the treatment of diabetes such as but not limited to GLP-1 and GIP receptor agonists * Prior or planned surgical, endoscopic and/or device-based therapy treatment for obesity * Self-reported, intentional or unintentional, change in body weight (over \~10%) within \~three months of screening * Known heart failure or clinically significant valvular heart disease * Implanted pacemaker or implantable cardioverter defibrillator (ICD) * Second or third-degree AV block, sino-atrial block, sick sinus syndrome * Known active malignancy including thyroid cancer * Known renal impairment (creatinine \>150µmol/L) * Clinically significant neurological disease * History of scleroderma * Participants on anticoagulant therapy * Known history of pancreatitis * Known inflammatory bowel disease * History of gallstones (unless previous cholecystectomy) * Severe gastroparesis or gastric emptying abnormality * Family history of multiple endocrine neoplasia * Needle-phobia * Planned pregnancy, current pregnancy, or breastfeeding * Current involvement in the active treatment phase of other research studies * Any other clinical reason which may preclude entry in the opinion of the investigator

129Xe MRI Cardiopulmonary

NCT06038630
Recruiting
Conditions Interstitial Lung Disease, Chronic Throm...
Phase PHASE2
Enrollment 125
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: Hyperpolarized Xe129 — Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.
  • Other: Oxygen Administration — Oxygen administration

Primary Outcomes

  • Change in RBC to Membrane Ratio Pre and Post Transfusion or Apheresis (Up to 5 days pre/post transfusion or apheresis)
  • Change in RBC (red blood cell) Chemical Shift After Oxygen Administration (Baseline, 1 day)
  • Change in RBC Oscillation Amplitude Post Therapy (Baseline, 3-6 months post-treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-01-12
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 125 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bastiaan Driehuys
Collaborators: National Institutes of Health (NIH)
Principal Investigators:
  • Joseph Mammarappallil, MD (PRINCIPAL_INVESTIGATOR) - Duke University
Contact Information
Study Contact:
Bastiaan Driehuys, PhD
919-684-7786
bastiaan.driehuys@duke.edu
Cody Blanton
919-668-7575
cody.blanton@duke.edu
Duke University Medical Center
Jennifer Korzekwinski
919-681-7362
jennifer.korzekwinski@duke.edu
Duke University Medical Center
Interventions
  • Drug: Hyperpolarized Xe129 — Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.
  • Other: Oxygen Administration — Oxygen administration
Study Locations (1 sites)
Duke University Medical Center, Durham, North Carolina 27710 United States
Eligibility Criteria
Inclusion Criteria for Healthy Volunteers: (Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial) 1. Outpatients of either gender, age \> 18 2. Willing and able to give informed consent and adhere to visit/protocol (Consent must be given before any study procedures are performed.) 3. Subject has no diagnosed pulmonary conditions 4. Subject has not smoked in the previous 5 years 5. Smoking history, if any, is less than or equal to 5 pack-years 6. No history of using other inhaled products more than 1/week for \> 1 year Inclusion Criteria for Transfusion and Phlebotomy Patients: 1. In-patient or outpatients of either sex, age \> 18 2. Willing and able to give informed consent and adhere to visit/protocol And one of the following: 1. Patients who are scheduled to receive a red cell transfusion for anemia. 2. Patients who are scheduled to undergo therapeutic phlebotomy to treat erythrocytosis or polycythemia 3. Healthy volunteers undergoing voluntary whole blood donation (healthy volunteer inclusion criteria noted above) Inclusion Criteria for Oxygen Administration Patients: 1. In-patient or outpatients of either sex, age \> 18 2. Willing and able to give informed consent and adhere to visit/protocol And one of the following categories (ILD, Dyspnea, CTEPH, or Healthy): 1. Interstitial Lung Disease or Dyspnea * Physician diagnosis of Interstitial Lung Disease by a pulmonologist using established criteria or physician referral of patient with dyspnea OR 2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) * Patients with a diagnosis of CTEPH, defined as mean PA pressure \>20 mmHg with a pulmonary vascular resistance \>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans OR 3. Healthy Volunteer (criteria noted above) Inclusion Criteria for Acute or Chronic Pulmonary Embolism Patients: 1. In-patient or outpatients of either sex, age \> 18 2. Willing and able to give informed consent and adhere to visit/protocol And one of the following categories (Acute or Chronic) 1. Acute Pulmonary Embolism * Patients presenting with acute PE 24-48hrs post-admission * Willing to return after 3-6 months of anti-coagulation therapy OR 2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) * Patients with a diagnosis of CTEPH, defined as mean PA pressure \>20 mmHg with a pulmonary vascular resistance \>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans Exclusion Criteria for All subjects: Subjects presenting with any of the following will not be included in the trial: 1. MRI is contraindicated based on responses to MRI screening questionnaire 2. Subject is pregnant or lactating 3. Resting O2 saturation \<90% with maximum supplemental O2 delivered by nasal canula 4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI 5. Subject has history of any known ventricular cardiac arrhythmia 6. Subject has history of cardiac arrest within the last year 7. Subject does not fit into 129Xe vest coil used for MRI 8. Subject cannot hold his/her breath for 10 seconds 9. Subject deemed unlikely to be able to comply with instructions during imaging 10. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
Conditions Vision Impairment and Blindness, Glaucom...
Phase NA
Enrollment 460
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

In this cohort study, the investigators will test vision screenings in Danish general practice for patients over 70 years of age with minimum one chronic condition. The main outcome is detection of vision impairment and secondary outcome is detection of conditions needing ophthalmologic follow-up but not presenting vision impairment at present time.

Design

Study type: Interventional Phases: Allocation: Intervention model: Sequential Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Other: focus on vision impairment in older patients in general practice — GP or GP nurse carry out the three vision tests. All patients visit optician shop collaborating with the project. An ophthalmologist review data from optometrists and provide an epicrisis to general practice. In case of acute conditions, the ophthalmologist is responsible for expedient treatment. If the patient needs further control by ophthalmologist within 12 month waiting time, general practice are responsible for referring the patient.

Primary Outcomes

  • Recruitment feasibility (From invitation to participate to enrollment within 4 weeks)
  • Adherence (From enrollment to completion of GP intervention within 3 weeks.)
  • Adherence (From enrollment to completion of optometrist testing within 5 months.)
  • Acceptability (From enrollment to interview within 12 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-15
Completion: 2027-07-15
Eligibility
Age: 70 Years and older
Sex: ALL
Volunteers: true
Enrollment: 460 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Copenhagen
Principal Investigators:
  • Frans B Waldorff (PRINCIPAL_INVESTIGATOR) - Center for Almen Medicin, KU
Contact Information
Study Contact:
Catharina Thiel Sandholdt, phd
+4531646460
casa@sund.ku.dk
Frans Boch Waldorff, prof
fransw@sund.ku.dk
Catharina Thiel Sandholdt
004531646460
casa@sund.ku.dk
GP practices
Interventions
  • Other: focus on vision impairment in older patients in general practice — GP or GP nurse carry out the three vision tests. All patients visit optician shop collaborating with the project. An ophthalmologist review data from optometrists and provide an epicrisis to general practice. In case of acute conditions, the ophthalmologist is responsible for expedient treatment. If the patient needs further control by ophthalmologist within 12 month waiting time, general practice are responsible for referring the patient.
Study Locations (2 sites)
GP practices, Copenhagen, Capital Region Denmark
GP practices, Køge, Region Sjælland Denmark
Eligibility Criteria
Inclusion Criteria: * +70 years * One or more chronic diseases * Are followed by GP du to chronic disease Exclusion Criteria: * Dementia diagnosis * Known eye-diseases or are currently followed by private ophtalmologist * Not able to understand Danish
Conditions Pregnancy, IUGR, Preeclampsia
Phase Not Applicable
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Pregnancy elicits adaptive changes in uteroplacental blood flow, which are altered at high altitude and may contribute to the observed 3-fold increase in intrauterine growth restriction (IUGR) and preeclampsia (PreE). The investigators propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA). If altered MA vasoreactivity is found, further studies may be able to link these changes to the increased rates of PreE and IUGR at altitude and contribute to the understanding of these two disorders.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Procedure: Collection of myometrial, cord blood, and placental tissue samples — We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).

Primary Outcomes

  • Changes in Myometrial artery dimensions (Up to 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2016-01
Completion: 2026-12-31
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: true
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Denver
Principal Investigators:
  • Lorna Moore, PhD (PRINCIPAL_INVESTIGATOR) - University of Colorado, Denver
Contact Information
Study Contact:
Lorna Moore, PhD
303-724-7474
lorna.moore@ucdenver.edu
Lorna Moore, PhD
University of Colorado Denver Anschutz Medical Campus
Anna Euser, MD
University of Colorado Denver Anschutz Medical Campus
Interventions
  • Procedure: Collection of myometrial, cord blood, and placental tissue samples — We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
Study Locations (1 sites)
University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado 80045 United States
Eligibility Criteria
Inclusion Criteria: * Women scheduled for cesarean delivery at University of Colorado Hospital (Denver, 1600 m) and St. Anthony's Summit Medical Center (Summit County, 3000 m) * Cesarean delivery at a prescheduled time without any labor, typically at 39 weeks gestation Exclusion Criteria: * Women will be excluded if there are co-existing medical diagnoses that are known to affect vascular parameters (i.e., diabetes mellitus, gestational diabetes, any hypertensive disorder of pregnancy, or a current smoker). * Women with multiple gestations and preterm deliveries will also be excluded.
Conditions Heart Failure With Reduced Ejection Frac...
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Diagnostic accuracy based on Area Under Curve (AUC) (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-10
Completion: 2029-03-31
Eligibility
Age: 18 Years – 90 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Steven Hsu, MD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins School of Medicine
Contact Information
Study Contact:
Steven Hsu, MD
410-502-0955
steven.hsu@jhmi.edu
Wendy I Foy
410-955-8491
wfoy2@jh.edu
Johns Hopkins Hospital
steven.hsu@jhmi.edu
Johns Hopkins Hospital
Interventions
N/A
Study Locations (1 sites)
Johns Hopkins Hospital, Baltimore, Maryland 21287 United States
Eligibility Criteria
Inclusion Criteria: * Adult patients aged between 18 and 90 years of age * Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40-50%) * Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure Exclusion Criteria: * Unable to interrupt VKA anticoagulation * Point of care International Normalized Ratio (INR) \> 1.5 * Pregnant patients * Acute hospitalization or decompensation within 2 weeks prior to study date * Participation in a study involving an investigational drug within 4 weeks prior to study date * Inability to lie flat in the supine position * Symptomatic hemodynamic instability at rest or during the procedure
Conditions Idiopathic Intracranial Hypertension (II...
Phase Not Applicable
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

1. To establish the correlation between the evolution of the body mass index in benign intracranial hypertension and the response to treatments. 2. To establish the BMI at which this disease occurs. 3. To establish how much the BMI must be reduced to cure this disease. 4. To assess the evolution and response to treatments of sick people who DO NOT reduce or even continue to increase their BMI despite treatment with Acetazolamide or a possible CSF diversion

Design

Study type: Observational Observational model: Case Control Time perspective: Other

Interventions / Regimen

  • Other: Weight loss without pharmacotherapy — The study will record the weight of the patients with Idiopathic Intracranial Hypertension every three months. It will correlate with the response to the different treatment modalities (weight loss with no other intervention, diuretic drugs (acetazolamide), lumboperitoneal shunt, or ventriculoperitoneal shunt). No medication will be provided to help lose weight.

Primary Outcomes

  • Response to treatment (Through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-06-27
Completion: 2028-05-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Valencia
Contact Information
Study Contact:
Vicente Vanaclocha, Professor
+ 34 963 13 18 00
vivava@uv.es
Teresa Moratal, Secretary
+ 34 963 13 18 00
moratal_ter@fihguv.es
Vicente Vanaclocha, Professor
+34 963 13 18 00
vivava@uv.es
Consorcio Hospital General Universitario de Valencia
Interventions
  • Other: Weight loss without pharmacotherapy — The study will record the weight of the patients with Idiopathic Intracranial Hypertension every three months. It will correlate with the response to the different treatment modalities (weight loss with no other intervention, diuretic drugs (acetazolamide), lumboperitoneal shunt, or ventriculoperitoneal shunt). No medication will be provided to help lose weight.
Study Locations (1 sites)
Consorcio Hospital General Universitario de Valencia, Valencia, Valencia 46015 Spain
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years and older at the time of enrollment. There is no upper age limit to ensure inclusivity across age ranges. * A confirmed diagnosis of Idiopathic Intracranial Hypertension, established according to the Dandy criteria. * The diagnostic process must exclude other potential causes of increased intracranial pressure as detailed in the 'Diagnosis' section, ensuring an accurate identification of idiopathic cases. Exclusion Criteria: * A diagnosis other than IIH, specifically: tension-type headache, Chiari I malformation, or any other headache disorder unrelated to IIH. * The presence of secondary causes of increased intracranial pressure (e.g., structural brain abnormalities, venous sinus thrombosis, or medication-induced factors).
Conditions IIH - Idiopathic Intracranial Hypertensi...
Phase NA
Enrollment 80
Locations 15 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Background and study aims Idiopathic intracranial hypertension (IIH) is a neurological condition characterised by increased pressure inside the skull, called intracranial pressure (ICP). It is more common in women of reproductive age with obesity. Common symptoms of IIH include headaches, blurred vision and ringing in the ears. If left untreated, the disorder may cause blindness. The majority of patients with IIH are managed with weight loss and medications. Fewer than 10% of patients develop progressive visual loss and require urgent intervention to reduce ICP and preserve vision. This trial will compare the two most common interventions performed in the UK and evaluate their clinical and cost-effectiveness. The first is called cerebrospinal fluid (CSF) shunting and involves a procedure where a thin tube called a shunt is implanted in the body to drain brain fluid. The second is called dural venous sinus stenting (DVSS) and involves a procedure where a metallic mesh tube called a stent is implanted inside a brain blood vessel. Both procedures can preserve vision, but there is no strong evidence to support one over the other. Participants will have the same chance to be treated with CSF shunting or DVSS. The aim of the trial is to know which intervention is the most effective to save the vision and the most cost-effective. Who can participate? Adults with a diagnosis of IIH at risk of permanent sight loss What does the study involve? The trial will be conducted in NHS hospitals located in England, Wales and Scotland. Participants are randomly allocated to undergo cerebrospinal fluid (CSF) shunting or dural venous sinus stenting (DVSS). Afterwards the participants will be asked to attend 11 hospital appointments and one telephone appointment. This follow-up will take 2 years from start to finish. Participants will be closely monitored for any side effects and potential device failure, and for changes in vision, headaches and quality of life. The researchers will also collect health data from NHS Digital (the national custodian of NHS health and social care data). What are the possible benefits and risks of participating? There are no direct benefits from taking part in the trial but the information gained from this trial may help improve treatment for adults with IIH in the future. Participants may be seen more often and/or feel more supported as a consequence of their involvement in the trial. As with any intervention, there are risks and complications, but there are no additional disadvantages or risks involved in taking part in this trial. Both CSF shunting and stenting are treatments for IIH (shunting is widely used internationally, and in some hospitals, stenting is used as part of the standard of care). Participants require an intervention to prevent sight loss. None of these treatments is experimental but at present, there is not enough information to determine which treatment is most suitable and provides the higher level of health…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: CSF shunt — CSF shunt may be ventriculoperitoneal (VP) or lumboperitoneal (LP) at the discretion of the treating medical team.
  • Device: DVSS — Dural Venous Sinus Stent. Exact make and model of device not mandated by protocol.

Primary Outcomes

  • Global thickness of the retinal nerve fibre layer (RNFL) over 6 months, as measured by OCT (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-18
Completion: 2028-05-28
Eligibility
Age: 18 Years – 63 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Birmingham
Collaborators: National Institute for Health Research, United Kingdom
Contact Information
Study Contact:
Alexandra Sinclair, MBChB, FRCP, PhD
+44 121 414 8040
a.b.sinclair@bham.ac.uk
IIH Intervention Mailbox
+44 121 371 8107
iihintervention@trials.bham.ac.uk
Georgios Tsermoulas
The Queen Elizabeth Hospital
Interventions
  • Device: CSF shunt — CSF shunt may be ventriculoperitoneal (VP) or lumboperitoneal (LP) at the discretion of the treating medical team.
  • Device: DVSS — Dural Venous Sinus Stent. Exact make and model of device not mandated by protocol.
Study Locations (15 sites)
The Queen Elizabeth Hospital, Birmingham, United Kingdom
Bristol Eye Hospital, Bristol, United Kingdom
Southmead Hospital, Bristol, United Kingdom
Addenbrooke's Hospital, Cambridge, United Kingdom
University Hospital of Wales, Cardiff, United Kingdom
Princess Alexandra Eye Pavillion, Edinburgh, United Kingdom
Queen Elizabeth University Hospital, Glasgow, United Kingdom
Royal Hull Infirmary, Hull, United Kingdom
Leeds General Infirmary, Leeds, United Kingdom
King's College Hospital, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of IIH by the IIH consensus guidelines with papilloedema and at risk of visual loss. 2. Presence of papilloedema (Frisén grade ≥ 3) in at least one eye 3. Age 18 to \< 64 years at the time of consent. 4. Patients must be suitable for and willing to proceed with both CSF shunting (VP or Lumboperitoneal shunts only) and DVSS. 5. Able to provide written informed consent. Exclusion Criteria: 1. Presence of current venous sinus thrombosis on diagnostic brain imaging by either MRI, MRV or CTV 2. Previous surgery for IIH including, optic nerve sheath fenestration, CSF shunting procedures, sub-temporal decompression and DVSS. 3. Previous bariatric surgery within the last 3 months 4. Patients with a past ophthalmic history, except refraction error, affecting the eligible eyes (study eyes) that could affect the vision. 5. Patient is, at the time of signing the informed consent, a user of recreational or illicit drugs (including marijuana) or has had a recent history (within the last year) of drug or alcohol abuse or dependence, in the opinion of the investigator. 6. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study. 7. Have participated in any other interventional study within 30 days prior to the screening visit (of note participation in the IIH Life database or other observational studies will not prevent enrolment to this study). 8. Previous randomisation for treatment in the present study. 9. Pregnant. 10. Absolute or serious contraindication to standard anti-thrombotic regimen peri and post stenting. 11. Secondary causes of raised intracranial pressure. (Refer to Protocol appendix 3 for additional information.) 12. History of significant documented iodine-based contrast allergy. 13. History of documented allergy to nitinol or nickel. 14. Absolute or serious contraindication for general anaesthesia. 15. Previous diagnosis of a hypercoagulable state (Factor V Leiden, Protein C or S deficiency, Anticardiolipin antibodies, Lupus anticoagulant, B2-glycoprotein-1 antibodies, or Hyperhomocysteinaemia). 16. Currently requiring full anticoagulation for other medical reasons, such as atrial fibrillation, artificial valves, deep vein thrombosis or pulmonary embolism. 17. Documented prior non-traumatic intracranial haemorrhage. 18. History of deep vein thrombosis or pulmonary embolism (within the last 24 months). 19. History of severe carotid atherosclerotic disease. 20. History of heart failure, dilated cardiomyopathy or congenital heart disease, etc. that are assessed as at high thrombotic risk. 21. Presence of intracranial vascular malformation considered clinically symptomatic (current or within 24 months). 22. Anatomical anomaly of the venous sinus which would prevent safe catheterisation and stenting (e.g. multi-channel sinus).
Conditions Hypertension, Pregnancy-Induced, HELLP S...
Phase Not Applicable
Enrollment 1106
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Preeclampsia is a serious high blood pressure condition that can develop during pregnancy. It is one of the leading causes of death and illness for mothers and babies in Africa. Doctors find it hard to tell which women with high blood pressure in pregnancy will go on to become seriously ill, because the tests available today are not accurate enough and are often not available in local clinics. Two proteins in the blood, called sFlt-1 and PlGF, may help predict who is at risk. The balance between them (the sFlt-1/PlGF ratio) has been useful in other parts of the world, but it has not been properly tested in African women. New rapid tests can measure these proteins at the clinic in minutes, using a small blood or urine sample, without a large laboratory. This study will look at how well these tests work in African women. Researchers will do two things. First, they will work out the result levels that best predict whether a woman will or will not develop severe preeclampsia in the following weeks, using a well-established laboratory test as the standard for comparison. Second, they will check how closely the rapid clinic tests match that laboratory standard. The study will also look at what these tests cost and whether using them could save money for families and health services. The study will include about 1,106 pregnant women at large maternity hospitals in Zimbabwe, Rwanda and Tanzania. Women may join if they are between 23 and 37 weeks pregnant with one baby and their care team suspects preeclampsia, for example because of raised blood pressure, protein in the urine, or symptoms such as headache, swelling or vision changes. Taking part does not change a woman's medical care in any way. Women will attend their usual pregnancy visits, plus study visits at 1 week, 2 weeks and 4 weeks, at delivery, and about 4 weeks after birth. At these visits the study team will record health information and collect blood and urine samples. About 15 ml of blood (around one tablespoon) is collected at each visit. The test results are not used to make any decisions about a woman's treatment. Doctors and nurses caring for her will not see them, and neither will she. All treatment decisions stay with her own healthcare team. Routine tests such as blood counts and liver tests are shared with her care team as usual. The results of this study may help clinics in Africa spot dangerous preeclampsia earlier, so mothers and babies can be treated in time.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Optimal sFlt-1/PlGF ratio cut-off values for predicting preeclampsia with severe features (derivation cohort) (Within 4 weeks after Visit 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-02-05
Completion: 2027-02-28
Eligibility
Age: 18 Years – 50 Years
Sex: FEMALE
Volunteers: false
Enrollment: 1106 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Africa Clinical Research Network (ACRN)
Contact Information
Study Contact:
Tariro Makadzange
+18572008374
tariro.makadzange@acrnhealth.com
Professor Chiratidzo Ndhlovu
+263772412701
rati.ndhlovu@acrnhealth.com
Mutala Trust
Interventions
N/A
Study Locations (1 sites)
Mutala Trust, Harare, Harare 263 Zimbabwe
Eligibility Criteria
Inclusion Criteria: * Gestational age between 23 weeks 0 days and 36 weeks 6 days, established by ultrasound performed at 22 weeks of gestation or earlier Singleton pregnancy Suspicion of a clinical diagnosis of preeclampsia based on one or more of the following: new onset of elevated blood pressure (systolic ≥130 mmHg or diastolic ≥80 mmHg); aggravation of pre-existing hypertension; new onset of protein in urine; aggravation of pre-existing proteinuria; or one or more other reasons for clinical suspicion of preeclampsia Other reasons for clinical suspicion include preeclampsia-related symptoms (epigastric pain, excessive oedema or severe swelling of the face, hands or feet, headache, visual disturbances, or sudden weight gain greater than 1 kg per week in the third trimester) or preeclampsia-related findings (low platelets, elevated liver transaminases, suspected intrauterine growth restriction, or abnormal uterine perfusion on Doppler sonography with mean pulsatility index above the 95th percentile in the second trimester and/or bilateral uterine artery notching, where available) Not currently enrolled in any other study or receiving an investigational medicinal product Able to provide informed consent Exclusion Criteria: * Multiple pregnancy (for example twins or triplets) Proteinuria 2+ or greater on dipstick AND elevated blood pressure (systolic ≥140 mmHg and/or diastolic ≥90 mmHg, reproducible on two occasions) Proteinuria 2+ or greater on dipstick and current antihypertensive treatment Confirmed diagnosis of HELLP syndrome No verified or documented ultrasound scan performed prior to 22 weeks of gestation to establish gestational age
Conditions Breast Cancer Stage I, Breast Cancer Sta...
Phase PHASE2
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to determine how the duration of hormone blocking (endocrine) therapy given prior to surgery (called "neoadjuvant" treatment) affects breast cancer. The main questions the trial aims is answer are: 1. How breast cancer responds to endocrine therapy given prior to surgery? 2. To predict tumor pre-operative endocrine prognostic index (PEPI) score for subjects enrolled in cohort B or C Participants with early-stage breast cancer (Stage I-III) who are eligible for Neoadjuvant Endocrine Therapy (NET) will be enrolled in the study. Participants will: * receive endocrine therapy as part of regular care for breast cancer * consent to samples of blood and tissue evaluation to determine how endocrine therapy effects the tumor * participate in this research anywhere from 2 weeks to 1 year, depending on duration of endocrine therapy and when surgery will be performed

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Neoadjuvant endocrine therapy — Cohort A: Short duration NET. Patients in this cohort can be treated with NET up to 8weeks (\<= 8 weeks)
  • Drug: Neoadjuvant endocrine therapy — Cohort B: Intermediate duration NET. Patients in this cohort can be treated with NET \> 8weeks but \<=24 weeks
  • Drug: Neoadjuvant endocrine therapy — Cohort C: Extended duration NET. Patients in this cohort can be treated with NET \>24 weeks but \<= 52 weeks

Primary Outcomes

  • Response to neoadjuvant endocrine therapy (NET) (From enrollment to the end of treatment at <=52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-10-01
Completion: 2028-10
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: George Washington University
Contact Information
Study Contact:
Pavani Chalasani, MD
202-741-2277
pchalasani@mfa.gwu.edu
Richard Lush, PhD
202-994-0329
rmlush3@gwu.edu
George Washington-Medical Faculty Associates
Interventions
  • Drug: Neoadjuvant endocrine therapy — Cohort A: Short duration NET. Patients in this cohort can be treated with NET up to 8weeks (\<= 8 weeks)
  • Drug: Neoadjuvant endocrine therapy — Cohort B: Intermediate duration NET. Patients in this cohort can be treated with NET \> 8weeks but \<=24 weeks
  • Drug: Neoadjuvant endocrine therapy — Cohort C: Extended duration NET. Patients in this cohort can be treated with NET \>24 weeks but \<= 52 weeks
Study Locations (1 sites)
George Washington-Medical Faculty Associates, Washington D.C., District of Columbia 20037 United States
Eligibility Criteria
Inclusion Criteria: * Be capable of understanding the investigational nature of the study and all pertinent aspects of the study * Be capable of signing and providing written consent in accordance with institutional and federal guidelines * Histologically or cytologically confirmed diagnosis of invasive carcinoma of the breast * Clinical stage 1 to 3 breast cancer * Candidate for surgical resection * Estrogen receptor \> 10% positive stained cells based on most recent tumor biopsy and documented by a local laboratory or medical record. * HER2 negative or HER2 low breast cancer based on the most recent tumor biopsy and documented by a local laboratory or medical record. HER2 negative tumor is defined per American Society of Clinical Oncology and the College of American Pathologists guidelines, 2018. Patients with HER2 low tumors are eligible as long as patients are not candidates for any HER2 directed therapy. * Ability to take oral medication * Be willing and able to comply with scheduled visits, treatment plan, and follow up with research staff * Age ≥ 21 years Exclusion Criteria: * Inability to comply taking NET * Inability to comply to study procedures
Conditions Breast Cancer, Clinically Assessed Negat...
Phase NA
Enrollment 311
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The OMSLNB trial adopts a prospective, single-arm, non-inferiority, phase-II, open-label study design. Patients with unilateral invasive breast cancer (tumor ≤3cm) and assessed as cN0 will be eligible for inclusion, enrolled patients are required to complete 2 or more imaging tests including axillary ultrasound assessed as axillary lymph node negative, and other tests including MRI, PET-CT, \[18F\]-FDG PET-MRI, eligible patients will avoid axillary surgery but will undergo breast surgery, which is not limited to breast-conserving surgery (BCS). So as to decrease the edema of upper arm, and finally improve the quality of life of the patients.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Omit SLNB — All patients enrolled have to receive two or more imaging tests including axillary ultrasound assessed as axillary lymph node negative, and other tests including MRI, PET-CT, \[18F\]-FDG PET-MRI, axillary surgery will be omitted for eligible patients, and BCS or mastectomy (allowing breast reconstruction) will be chosen voluntarily by the patient under the premise of ensuring therapeutic efficacy, patients receiving BCS must undergo whole breast irradiation (WBI) after surgery, and the radiotherapy target area does not include the axillary region.

Primary Outcomes

  • invasive Disease-Free Survival (iDFS) (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-21
Completion: 2027-10-01
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 311 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Principal Investigators:
  • Xiaoming Zha, MD (PRINCIPAL_INVESTIGATOR) - The First Affiliated Hospital with Nanjing Medical University
Contact Information
Study Contact:
Jue Wang, MD
025-68306360
wangjue200011@njmu.edu.cn
Xuan Li, MD
18154489540
lixuan1204@stu.njmu.edu.cn
Jue Wang, MD
025-68306360
wangjue200011@njmu.edu.cn
the First Affiliated Hospital of Nanjing Medical University
Interventions
  • Procedure: Omit SLNB — All patients enrolled have to receive two or more imaging tests including axillary ultrasound assessed as axillary lymph node negative, and other tests including MRI, PET-CT, \[18F\]-FDG PET-MRI, axillary surgery will be omitted for eligible patients, and BCS or mastectomy (allowing breast reconstruction) will be chosen voluntarily by the patient under the premise of ensuring therapeutic efficacy, patients receiving BCS must undergo whole breast irradiation (WBI) after surgery, and the radiotherapy target area does not include the axillary region.
Study Locations (1 sites)
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged 18-70 years; 2. Pathologically confirmed invasive breast cancer (regardless of pathological type) with a tumor diameter ≤ 3 cm, and planning to undergo breast surgery; 3. Negative axillary lymph nodes assessed by physical examination and imaging (2 or more of the following tests including ultrasound, breast MRI, breast PET-CT, breast PET-MRI, breast PET); 4. All patients are required to undergo immunohistochemical staining for Estrogen Receptor (ER), Progesterone Receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki-67 proliferation index, and further fluorescence in situ hybridization (FISH) should be performed in HER2 2+ cases; 5. Good compliance, normal comprehension and ability to receive treatment and follow-up as required; 6. ECOG score 0-1; 7. Patients volunteered for this study and signed the informed consent form. Exclusion Criteria: 1. Bilateral/lactating/pregnant breast cancer; 2. Previous history of malignant tumor or neoplasm; 3. Clinical or imaging confirmation of distant metastasis; 4. History of previous surgery on the affected axilla; or history of surgery affecting the function of the upper extremity; 5. Prior history of radiotherapy to the breast or chest; 6. Positive pathological margins after breast-conserving surgery or mastectomy; 7. Severe coagulation disorder, or a serious systemic disease, or an uncontrollable infection; 8. Aspartate aminortransferse (AST) and Alanine aminotransferase (ALT) ≥ 1.5 times the upper limit of normal, alkaline phosphatase ≥ 2.5 times the upper limit of normal, total bilirubin ≥ 1.5 times the upper limit of normal, serum creatinine ≥ 1.5 times the upper limit of normal; left ventricular injection fraction (LVEF) \< 50% on cardiac ultrasound; 9. Inability to complete the full course of follow-up adjuvant therapy as prescribed by the doctor for various reasons; 10. No personal freedom and independent civil capacity; 11. Presence of mental disorders, addictions, etc; 12. Not eligible for enrollmentas as judged by the investigator.